![](/img/cover-not-exists.png)
A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours
Patrick Schöffski, Ahmad Awada, Herlinde Dumez, Thierry Gil, Sylvie Bartholomeus, Pascal Wolter, Martine Taton, Holger Fritsch, Patricia Glomb, Gerd MunzertVolume:
48
Year:
2012
Language:
english
Pages:
187
DOI:
10.1016/j.ejca.2011.11.001
File:
PDF, 245 KB
english, 2012